Bargain Alert: Sanofi could be in the Buy Zone

Bargain Alert: Sanofi could be in the Buy Zone. Sanofi was in limelight in the last couple of days. And this time it is for Zika Vaccine, yes the drug maker with a large market cap, is currently working with U.S. Army to develop a Zika vaccine. Despite this good news, the stock has failed to do well. Infact the year 2016 has been like a roller coaster ride for Sanofi. The stock dropped more than 18% in the previous year. The declining sales, further sent the stock lower, despite this there was a 6% rise EBIT for the first half of this year (an indication to good EPS growth). Their balance sheet looks good. Sanofi’s future looks promising as they plan on launching 13 novel drugs by 2020. This stock is good buy because of strong underlying fundamentals.